---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-298551"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2025-11-26T23:59:59+00:00"
generated_at: "2026-05-16T16:33:02.135121+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio discontinues NUV-1511 DDC program; redirects $100-150M to pipeline

## Summary
- Discontinued NUV-1511 due to inconsistent efficacy across cohorts; DDC platform continues.
- Projected $100-150M in R&D/CMC costs through 2029 reallocated to other pipeline molecules.
- First patient enrolled in part 2 of G203 study of safusidenib for IDH1-mutant glioma.
- Continued investment in IBTROZI (taletrectinib) commercial launch and TRUST-IV adjuvant study.

## SEC filing metadata
- accession: 0001193125-25-298551
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2025-11-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312525298551/0001193125-25-298551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312525298551/d82457d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-298551
- JSON: https://secwatch.observer/filing/0001193125-25-298551.json
- Plain text: https://secwatch.observer/filing/0001193125-25-298551.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.